These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 2050157

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Antiemetic treatment of chemotherapy-induced nausea in ovarian carcinoma patients.
    Sorbe B, Hallén C.
    Gynecol Oncol; 1989 Aug; 34(2):141-4. PubMed ID: 2568970
    [Abstract] [Full Text] [Related]

  • 3. Betamethasone-dixyrazine versus metoclopramide as antiemetic treatment in cancer chemotherapy.
    Sorbe B, Hallén C.
    Acta Oncol; 1988 Aug; 27(4):357-60. PubMed ID: 3060151
    [Abstract] [Full Text] [Related]

  • 4. Betamethasone-dixyrazine combination versus high-dose metoclopramide as antiemetic treatment in doxorubicin and cisplatin chemotherapy.
    Sorbe B, Hallén C, Skåre NG, Underskog I.
    Radiother Oncol; 1989 Jun; 15(2):161-7. PubMed ID: 2762589
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis.
    Sorbe BG, Högberg T, Glimelius B, Schmidt M, Wernstedt L, Hansen O, Sörensen BT, Räisänen I, van Oosterom AT, de Bruijn KM.
    Cancer; 1994 Jan 15; 73(2):445-54. PubMed ID: 8293412
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
    Bonneterre J, Chevallier B, Metz R, Fargeot P, Pujade-Lauraine E, Spielmann M, Tubiana-Hulin M, Paes D, Bons J.
    J Clin Oncol; 1990 Jun 15; 8(6):1063-9. PubMed ID: 2140854
    [Abstract] [Full Text] [Related]

  • 12. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
    J Clin Oncol; 1997 Jan 15; 15(1):124-30. PubMed ID: 8996133
    [Abstract] [Full Text] [Related]

  • 13. Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial.
    Gebbia V, Testa A, Valenza R, Cannata G, Tirrito ML, Gebbia N.
    Cancer; 1995 Nov 15; 76(10):1821-8. PubMed ID: 8625054
    [Abstract] [Full Text] [Related]

  • 14. A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.
    Chevallier B, Cappelaere P, Splinter T, Fabbro M, Wendling JL, Cals L, Catimel G, Giovannini M, Khayat D, Bastit P, Claverie N.
    Support Care Cancer; 1997 Jan 15; 5(1):22-30. PubMed ID: 9010986
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Antiemetic combination for PAC (cisplatin-adriamycin-cyclophosphamide) chemotherapy-induced emesis in ovarian cancer.
    Martin-Jimenez M, Diaz-Rubio E, Gonzalez Larriba JL, Sangro B.
    Eur J Gynaecol Oncol; 1987 Jan 15; 8(2):98-102. PubMed ID: 3552683
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A double-blind trial comparing antiemetic efficacy and toxicity of metoclopramide versus methylprednisolone versus domperidone in patients receiving doxorubicin chemotherapy alone or in combination with other antiblastic agents.
    Basurto C, Roila F, Bracarda S, Tonato M, Ballatori E, Del Favero A.
    Am J Clin Oncol; 1988 Oct 15; 11(5):594-6. PubMed ID: 3177262
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.